WaveBreak's Technology Platform The relatively recent understanding that oligomers resulting from errant protein folding are the toxic entities directly responsible for neurotoxicity in Parkinson's disease, Alzheimer's disease, and ALS has defined a new approach to treating a central molecular cause of neurodegeneration. "Our goal is to break open a new frontier of treatment for the rapidly expanding and debilitating wave of neurodegenerative diseases such as Parkinson's disease, Alzheimer's disease, and ALS that have enormous unmet medical need." "We are making strong progress in the development of a new class of oral, small-molecule therapeutics for neurodegenerative diseases, focusing first on inhibiting α-synuclein oligomers and aggregation for the treatment of Parkinson's disease," said Bart Henderson, CEO. This new name reflects the company's focus on developing small-molecule therapeutics that inhibit the production of fleeting protein intermediates-the oligomers-that are at the source of the protein misfolding and aggregation assembly pathways in the major neurodegenerative diseases.
BOSTON, Ap/PRNewswire/ - Wren Therapeutics announced today that the company has changed its name to WaveBreak.
0 kommentar(er)
